Ole Haagen Nielsen, MD, DMSc; Mark Andrew Ainsworth, MD, PhD, DMSc
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-0605.
Requests for Single Reprints: Ole Haagen Nielsen, MD, DMSc, Department of Gastroenterology, Medical Section D112M, Herlev Hospital, 75 Herlev Ringvej, DK-2730 Herlev, Denmark.
Current Author Addresses:Drs. Nielsen and Ainsworth: Department of Gastroenterology, Medical Section D112M, Herlev Hospital, 75 Herlev Ringvej, DK-2730 Herlev, Denmark.
Nielsen O., Ainsworth M.; Which Biological Agents Are Most Appropriate for Ulcerative Colitis?. Ann Intern Med. 2014;160:733-734. doi: 10.7326/M14-0605
Download citation file:
Published: Ann Intern Med. 2014;160(10):733-734.
Ulcerative colitis (UC) is the most prevalent inflammatory bowel disease, and its global incidence and prevalence is increasing (1). The classic standard treatment options consisted of 5-aminosalicylic acids, glucocorticoids, and immunomodulators (thiopurines and cyclosporine) for decades. Huge advances have been made recently because detailed insights into the immune system response in this disease have led to the development of artificially synthesized monoclonal antibodies that block key mediators of inflammation (such as tumor necrosis factor-α), including infliximab, adalimumab, and golimumab (2), as well as integrins, including vedolizumab, which selectively block the α4β7/mucosal addressin cell adhesion molecule–1 (3–5).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Inflammatory Bowel Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only